ADD/ADHD News

Methylphenidate use was significantly associated with sleep problems and several different types of insomnia, according to a meta-analysis published in Journal of Clinical Psychiatry.

The FDA has permitted marketing of the first, prescription-only medical device for ADHD — the Monarch external Trigeminal Nerve Stimulation, or eTNS, System — for children aged 7 to12 years not currently taking prescription ADHD medication, according to a press release.

In a large birth cohort study, researchers found that preschool-aged children who had 2 hours of screen time per day were at increased risk for clinically significant externalizing problems, inattention problems and ADHD.

Trigeminal nerve stimulation, or TNS, a minimal-risk noninvasive neuromodulation method, improved symptoms and brain functioning in children with ADHD in a blinded sham-controlled pilot study.

Infectious Diseases in Children asked Janet R. Gilsdorf, MD, DSc (Hon), FPIDS, a past president of the Pediatric Infectious Diseases Society and the Robert P. Kelch Research Professor Emerita at the University of Michigan Medical Center, how she saw the value of the pediatric ID specialty, why she went into the field and what it means to her.

Pediatric infectious disease specialists are the lowest paid physicians compared with all other medical specialties, according to a recent report.

The FDA has approved Adhansia XR extended-release capsules CII, a central nervous system stimulant, for the treatment of ADHD in certain patients aged 6 years and older, according to a press release.

Among children with autism spectrum disorder, study findings revealed that ADHD symptoms were linked to poorer adaptive behavior across all settings and after controlling for key confounders.

Treatment with daily dasotraline 4 mg significantly improved ADHD symptoms and behaviors in children aged 6 to 12 years, according to a 6- week, placebo-controlled study.

Nonmedical use of prescription stimulant medications is highly prevalent in the U.S. and can lead to serious adverse health outcomes, especially when taken by nonoral routes, according to study data.